Bevacizumab, when added to chemotherapy regimen for elderly patients with lung cancer, does not increase survival rates
The researchers analyzed data on 5,670 patients 65 years and older from the SEER-Medicare database, with stage IIIB or stage IV non-squamous cell NSCLC, controlling for demographic and clinical patient attributes. Given the findings of their study and that of other research, the authors conclude that bevacizumab should not be considered standard of care in this context. They recommend that clinicians exercise caution in making treatment recommendations and should use bevacizumab judiciously for their older patients. This study was supported by the Agency for Healthcare Research and Quality (Contract No. 290-10-00006).
See "Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer," by Junya Zhu, M.S., Dhruv B. Sharma, Ph.D., Stacy W. Gray, M.D., and others in the April 18, 2012 Journal of the American Medical Association 307(15), pp. 1593-1601.